...
首页> 外文期刊>Frontiers in Cell and Developmental Biology >Pluripotent Stem Cells for the Treatment of Retinal Degeneration: Current Strategies and Future Directions
【24h】

Pluripotent Stem Cells for the Treatment of Retinal Degeneration: Current Strategies and Future Directions

机译:多能干细胞用于治疗视网膜变性:目前的策略和未来方向

获取原文
           

摘要

Stem cells have been part of the biomedical landscape since the early 1960s. However, the translation of stem cells to effective therapeutics have met significant challenges, especially for retinal diseases. The retina is a delicate and complex architecture of interconnected cells that are steadfastly interdependent. Degenerative mechanism caused by acquired or inherited diseases disrupt this interconnectivity, devastating the retina and causing severe vision loss in many patients. Consequently, retinal differentiation of exogenous and endogenous stem cells is currently being explored as replacement therapies in the debilitating diseases. In this review, we will examine the mechanisms involved in exogenous stem cells differentiation and the challenges of effective integration to the host retina. Furthermore, we will explore the current advancements in trans-differentiation of endogenous stem cells, primarily Müller glia.
机译:自20世纪60年代初以来,干细胞是生物医学景观的一部分。然而,干细胞对有效治疗剂的翻译已经符合显着的挑战,特别是对于视网膜疾病。视网膜是一种微妙而复杂的互连细胞架构,其具有坚定不相的相互依赖性。由获得或遗传疾病引起的退行性机制会破坏这种互连,使视网膜破坏并导致许多患者的严重视力丧失。因此,目前正在探讨外源性和内源干细胞的视网膜分化作为衰弱疾病中的替代疗法。在本综述中,我们将研究外源干细胞分化所涉及的机制以及对宿主视网膜有效融合的挑战。此外,我们将探讨内源性干细胞跨分化的目前进步,主要是MüllerGlia。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号